• In early February 2026, AbbVie reported fourth-quarter 2025 sales of US$16,618 million and net income of US$1,816 million, alongside full-year 2025 sales of US$61.16 billion and net income of US$4.23 billion, and also filed for U.S. and European approval of Rinvoq for non-segmental vitiligo while preparing to present new immunology research at a Piper Sandler symposium.
• The combination of growing revenues after Humira’s loss of exclusivity, ongoing label expansion for Rinvoq, and active R&D communication highlights how AbbVie is leaning on its immunology pipeline to underpin its long-term earnings profile and dividend record.
• We’ll now examine how AbbVie’s resilient 2025 financials and new Rinvoq vitiligo filings may influence its existing investment narrative.

Outshine the giants: these 26 early-stage AI stocks could fund your retirement.

AbbVie Investment Narrative Recap

To own AbbVie today, you need to believe its immunology and oncology franchises can offset Humira’s decline while supporting its long dividend history. The latest 2025 results and Rinvoq vitiligo filings reinforce that story but do not materially change the near term focus on execution for Skyrizi and Rinvoq or the ongoing risk from pricing pressure and patent exposure.

The Rinvoq application for non segmental vitiligo is the most relevant update here, because it adds another potential use for a key immunology asset that management is using to support AbbVie’s earnings base and income stream after Humira.

Yet behind the resilient numbers, investors should be aware that concentrated dependence on a few immunology blockbusters could...

AbbVie's narrative projects $73.0 billion revenue and $20.8 billion earnings by 2028. This requires 7.7% yearly revenue growth and about a $17.1 billion earnings increase from $3.7 billion today.

Uncover how AbbVie's forecasts yield a $244.96 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Four members of the Simply Wall St Community currently see AbbVie’s fair value between US$244.96 and US$375.71 per share, reflecting a wide spread of individual models. Against that backdrop, concentrated exposure to a handful of immunology products and evolving pricing rules may affect how you think about AbbVie’s future earnings power and income resilience, so it can be useful to compare several of these viewpoints before deciding what the stock is worth to you.

Explore 4 other fair value estimates on AbbVie - why the stock might be worth as much as 62% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your AbbVie research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free AbbVie research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AbbVie's overall financial health at a glance.

Curious About Other Options?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 55 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.